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ABSTRACT
Background: The ATHENA (A Placebo-
Controlled, Double-Blind, Parallel Arm Trial to
Assess the Efficacy of Dronedarone 400 mg bid
for the Prevention of Cardiovascular
Hospitalization or Death from Any Cause in
Patients with Atrial Fibrillation/Atrial Flutter)
trial demonstrated a significant reduction (26%)
in the rate of first cardiovascular (CV)
hospitalization in dronedarone-treated patients
with paroxysmal or persistent atrial fibrillation/
flutter (AF/AFL). ATHENA was the first trial to
demonstrate a CV outcomes benefit, specifically
reduced CV hospitalizations, with an
antiarrhythmic drug. The objective of this
study was to assess the impact of dronedarone
treatment on healthcare resource utilization
among real-world patients with AF/AFL in
United States clinical practice.
Methods: This retrospective cohort study used
claims data from the MarketScan databases
(Truven Health, Durham, NC, USA) to identify
patients with C2 concurrent de novo pharmacy
claims for dronedarone (C180 days’ total
supply) between June 2009 and March 2011,
and with an AF/AFL diagnosis and no heart
failure-related hospitalization during the
12 months preceding the initial (index)
dronedarone claim. Annualized inpatient and
outpatient resource utilization were compared
between the pre-index (baseline) and post-index
(follow-up) periods.
Results: In total, 5,656 AF/AFL patients were
prescribed dronedarone for C6 months and
were followed for mean (standard deviation)
11.9 (4.7) months. Reductions in mean
numbers of annualized all-cause, CV- and AF-
related hospitalizations (*40–45%), and
emergency department visits (*30–45%) were
realized. These benefits were offset by increases
in office visits (*10–30%) and AF-related
prescription claims (74%) after dronedarone
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initiation. The sub-cohort of patients switching
to dronedarone from Prior Rhythm-Control
therapy (n = 2,080) showed similar reductions
in hospital and emergency department events.
Conclusions: This study suggests that
dronedarone use in real-world practice, as in
the ATHENA trial, results in substantial
reductions in hospital admissions, both in
first-line and second-line antiarrhythmic
treatment settings.
Keywords: Antiarrhythmic; Atrial fibrillation;
Atrial flutter; Cardiovascular hospitalizations;
Dronedarone
INTRODUCTION
Atrial fibrillation (AF) and atrial flutter (AFL)
collectively affect an estimated 3.3 million
adults in the USA and confer increased
cardiovascular and cerebrovascular risk [1].
Patients with AF/AFL are more likely than age-
matched individuals without AF/AFL to have
other cardiovascular and cardio-metabolic
conditions [1–3]. Moreover, the presence of
AF/AFL worsens the prognosis of patients with
cardiovascular comorbidities, elevates the risk
of stroke and doubles the risk of mortality [4, 5].
AF is considerably more frequent than AFL, and
accounts for [90% of all cases of AF/AFL [1]. In
the USA, AF-associated hospitalizations and
deaths have been increasing steadily over the
past 30 years [6], and one in three patients can
expect a cardiovascular-related hospitalization
within the first year following diagnosis of AF
[6].
Clinical trials have provided evidence of
significant improvements in patient-centered
outcomes in AF, including decreased rates of
stroke, cardiovascular hospitalization, and
cardiovascular mortality [7–9]. Whether trial-
tested outcomes translate into improved
outcomes in the real-world setting is not well
studied and remains an important clinical
question. Although randomized clinical trials
are important in establishing treatment efficacy,
their emphasis on internal validity often limits
the generalizability of their findings [10].
Differences in patient selection, treatment
conditions, and practice patterns between the
clinical trial and the real-world setting can
influence treatment outcomes [11]. Important
patient subgroups, including the elderly, and
those with coexisting morbidities, are
frequently under-represented in clinical trials
of cardiovascular drugs [12, 13]. Likewise, AF
clinical trial populations vary in their
representativeness to real-world AF patients
[14, 15].
Large, observational cohort studies can be
useful in bridging the gap between the highly
controlled environment of the randomized
clinical trial and routine clinical practice.
Observational studies can enroll more
heterogeneous populations, including older
patients and those with comorbidities, provide
extended patient follow-up, and incorporate a
diversity of outcome measures. Retrospective
cohort studies have been helpful in determining
the resource use and cost burden associated
with disease management among real-world
AF/AFL patients [8, 10, 16].
The recent ATHENA trial (A Placebo-
Controlled, Double-Blind, Parallel Arm Trial to
Assess the Efficacy of Dronedarone 400 mg bid
for the Prevention of Cardiovascular
Hospitalization or Death from Any Cause in
Patients with Atrial Fibrillation/Atrial Flutter;
NCT 00174785), demonstrated significant
reductions in cardiovascular-related
hospitalization rates among dronedarone-
treated patients with AF/AFL (26%) [9]. The
objective of this retrospective, observational
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study was to assess the impact of dronedarone
treatment on healthcare resource utilization




This study used administrative claims data from
the Thomson Reuters MarketScan Commercial
Claims and Encounter database and Medicare
Supplemental and Coordination of Benefits
database (Truven Health, Durham, NC, USA)
for the period June 2008–September 2011. The
Commercial Claims database contains health
claims records from privately insured
individuals and their dependents, whereas the
Medicare Supplemental database focuses on the
over 65-year-old population with employer-
sponsored Medicare-supplemental healthcare
insurance. Collectively, the databases capture
patient-level healthcare claims data from more
than 100 different insurance companies, Blue
Cross Blue Shield plans, and third-party
administrators. The claims data include
inpatient and outpatient information, health
and productivity data, laboratory data, and
hospital drug data. The MarketScan databases
include 43.1 million patients across the
continental USA, including 39.9 million
commercial lives and 3.2 million Medicare
lives with employer-sponsored supplemental
insurance (2009 data) [17]. The databases are
fully compliant with the Health Portability and
Accountability Act of 1996 (HIPAA), and all data
are de-identified to protect the privacy of
patients and providers. Accordingly,
institutional review board and ethics
committee approval was not required for the
study.
Patient Selection
Patients were C18 years of age, with a diagnosis
of AF and/or AFL (International Classification of
Diseases, Ninth Revision, Clinical Modification
[ICD-9-CM] codes 427.31 and 427.32,
respectively) [18] on C1 inpatient claim or C2
outpatient claims on different days between
June 2008 and September 2011, and received C2
prescriptions for dronedarone, amounting to
C180 days’ continuous supply, on separate
dates between June 2009 and March 2011. The
first prescription claim during this period was
identified as the index claim, and the date of
this claim was the index date. Patients were
required to have continuous medical and
prescription drug insurance coverage for
12 months prior to the index date (baseline
period) and for C6 months after the index date,
until 30 days after the end of the dronedarone
possession period or the end of the health plan
enrollment, whichever occurred first (follow-up
period). The dronedarone possession period was
defined as the time from the index date to the
end of the days-of-supply of the last
dronedarone prescription, allowing a grace
period of B30 days between exhaustion of
drug supply from one prescription and fill of
the next prescription. Patients were excluded if
they had evidence of transient AF/AFL, as
indicated by an ICD-9-CM diagnosis code for
hyperthyroidism or a prescription for
methimazole or propylthiouracil during the
baseline period or an AF/AFL diagnosis within
30 days of cardiac surgery; two or more
cardioversion procedures [Current Procedural
Terminology, 4th edition (CPT-4) procedure
codes 92960, 92961; ICD-9 procedure code
99.61] in the 3 months prior to the index date;
or were hospitalized for heart failure during the
baseline period.
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Patients satisfying the study eligibility
criteria comprised the full study population; a
subset of patients who received a rhythm-
control agent within 3 months prior to
initiation of dronedarone was identified (‘‘Prior
Rhythm-Control cohort’’).
Outcome Measures
Patient demographics were recorded at the time
of the index prescription claim. Clinical
characteristics, including comorbidities
(defined according to ICD-9-CM diagnosis
codes), Charlson Comorbidity Index (CCI)
score [19] and CHADS2 [Congestive heart
failure, history of Hypertension, Age
C75 years, Diabetes mellitus, and past history
of Stroke or TIA (transient ischemic attack)]
score [20], and AF-related medication (rhythm-
control, rate-control, and anticoagulation) use
were determined over the baseline period.
Healthcare resource utilization, comprising
inpatient services (hospital facility and
professional), outpatient medical services
(emergency department and office visits,
laboratory tests and procedures), and
outpatient pharmacy services, were determined
over the baseline and follow-up periods.
Inpatient and outpatient medical services were
stratified by cause (all-cause, cardiovascular-
related, and AF-related), and outpatient
pharmacy services were stratified by treatment
type (all-cause and AF-related). To control for
the variable duration of post-index follow-up,
resource utilization was calculated on an annual
basis. Office and emergency department visits
were defined as the number of days with an
outpatient claim, as the MarketScan databases
do not identify each individual visit. Resource
utilization was expressed as the number of
hospital admissions and total number of days
in hospital, the number of days with office and
emergency department visits, and the
proportion of patients with prescription drug
claims per patient-year (PPY) for each study
period. Intra-cohort comparisons of annualized
healthcare resource utilization between baseline
and follow-up periods were conducted for (1)
the full study population and (2) the Prior
Rhythm-Control cohort.
Statistical Analysis
Hospitalization rates, resource utilization, and
costs were calculated on an annual basis, as
follows: annualized outcome = outcome/
number of days in observation period 9 365.
The baseline period was of uniform duration
(365 days) for all patients. The post-index
follow-up period varied from patient to
patient. Bivariate statistics were used to
compare healthcare resource utilization
between the baseline and follow-up periods
(intra-cohort comparison). Student’s paired
t test was used for comparison of continuous
variables with a 5% significance level (a = 0.05).
All statistical analyses were carried out using SAS
Release 9.2 (SAS Institute, Inc., Cary, NC, USA).
The analysis in this article is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
RESULTS
Patient Characteristics
In total, 5,656 AF/AFL patients met the study
eligibility criteria (full study population) and
were prescribed dronedarone for C6 months.
The full study population was predominantly
male (62%), had a mean age of 68.3 years, and
included patients enrolled in managed care
systems as well as fee-for-service health plans
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(Table 1). A high proportion of patients had
comorbidities, most commonly hypertension
(66.8%), coronary artery disease (35.5%), and
diabetes (22.7%). During the baseline period,
most patients received rate-control (b-blocker
and calcium channel blocker) therapy (80.5%)
and anticoagulant (predominantly warfarin)
therapy (56.3%); less than one-half of patients
received rhythm-control (predominantly
amiodarone) therapy (41.3%). The mean
[standard deviation (SD)] duration of post-
index follow-up was 11.9 (4.7) months (range
6.0–26.1 months).
Of the 5,656 patients in the full study
population, 2,080 patients had received
rhythm-control treatment in the 3 months
prior to the index dronedarone prescription
claim (Prior Rhythm-Control cohort). The
demographic and baseline clinical
characteristics of this cohort closely mirrored
those of the full study population (Table 1),
with the exception of baseline AF-related
therapy, which for the Prior Rhythm-Control
cohort comprised rhythm-control therapy
(100%), rate-control therapy (80.3%), and
anticoagulation (67.1%). The mean (SD)
duration of follow-up for the Prior Rhythm-




Mean numbers of annualized all-cause,
cardiovascular- and AF-related hospitalizations,
and associated lengths of hospital stay were
significantly (P\0.0001) reduced from baseline
levels following initiation of dronedarone
treatment (Fig. 1). Significant reductions were
noted in the numbers of all-cause
hospitalizations (-39%) and emergency
department visits (-27%) and in the total
length of hospital stay (-35%) (all P\0.0001);
in contrast, there were significant increases in
the number of all-cause office visit claims (?7%)
and outpatient prescription claims (?24%)
(both P\0.0001) after dronedarone initiation
(Fig. 2). Similar reductions were noted in mean
numbers of cardiovascular-related and AF-
related hospitalizations (-42% and -46%
respectively, P\0.0001) and cardiovascular-
related and AF-related emergency department
visits (-41% and -45% respectively,
P\0.0001), and in total lengths of
cardiovascular-related and AF-related hospital
stay (-37% and -42%, P\0.0001). The
increases in mean numbers of cardiovascular-
and AF-related office visits (?12% and ?29%,
P\0.0001) and AF-related prescription claims
(?74%, P\0.0001) (Figs. 1, 2) were offset by the
reductions in hospitalizations and emergency
department visits.
Comparison of AF-related prescription drug
utilization before and after initiation of
dronedarone indicated high rates of uptake of
rate-control therapy during both study periods
(80.5% vs. 78.1%). Use of rhythm-control
agents other than dronedarone declined
between the baseline and follow-up period
(41.3% vs. 11.8%), whereas anticoagulant
coverage increased (56.3% vs. 68.5%). Mean
numbers of antiarrhythmic drug claims
increased almost fourfold from baseline levels
following initiation of dronedarone treatment
(7.5 vs. 1.9 claims PPY) (P\0.0001). This
increase was almost entirely due to claims for
dronedarone itself (mean 7.3 claims PPY), since
the follow-up period was marked by large
percent reductions in mean numbers of
prescription claims for amiodarone (-85%),
sotalol (-91%), and other antiarrhythmic
drugs (–89%) (all P\0.0001) (Fig. 3). Initiation
of dronedarone treatment was also associated
with increases in the mean number of
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Table 1 Baseline (pre-index) demographic and clinical characteristics of the full study population and the sub-population of
patients with prior rhythm-control therapy




Male (%) 62.0 61.9
Age, years, mean (SD) 68.3 (11.1) 68.4 (11.0)
Age category, n (%)
18–54 years 583 (10.3) 207 (10.0)
55–59 years 650 (11.5) 254 (12.2)
60–64 years 1,066 (18.9) 373 (17.9)
65–69 years 724 (12.8) 251 (12.1)
70–74 years 796 (14.1) 324 (15.6)
75–79 years 818 (14.5) 310 (14.9)
C80 years 1,019 (18.0) 361 (17.4)
Geographic region, n (%)
Northeast 604 (10.7) 189 (9.1)
North Central 1,719 (30.4) 591 (28.4)
South 2,226 (39.4) 817 (39.3)
West 1,097 (19.4) 477 (22.9)
Health plan type, n (%)
Comprehensive 2,035 (36.0) 697 (33.5)
HMO 490 (8.7) 208 (10.0)
PPO 2,430 (43.0) 913 (43.9)
POS 385 (6.8) 153 (7.4)
AF/AFL-related treatment, n (%)
Rhythm-control 2,336 (41.3) 2,080 (100.0)
Rate-control 4,551 (80.5) 1,671 (80.3)
Anticoagulation 3,186 (56.3) 1,396 (67.1)
Comorbidities, n (%)
Coronary artery disease 2,008 (35.5) 723 (34.8)
Congestive heart failure 668 (11.8) 291 (14.0)
Valvular heart disease 920 (16.3) 318 (15.3)
Peripheral vascular disease 388 (6.9) 129 (6.2)
Hypertension 3,776 (66.8) 1,364 (65.6)
Stroke/TIA 736 (13.0) 237 (11.4)
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prescription claims for anticoagulant drugs
(?65%), including warfarin (?46%) and
dabigatran (?2,400%) (all P\0.0001). In
contrast, numbers of prescription claims for
rate-control agents, including calcium channel
blockers and b-blockers, remained largely
unchanged after the introduction of
dronedarone (Table 2).
Prior Rhythm-Control Cohort
Similar changes in pattern of healthcare
resource utilization to those described in the
full study population occurred in the Prior
Rhythm-Control cohort after initiation of
dronedarone (Figs. 1, 2). Marked reductions in
the mean numbers of all-cause hospitalizations
(-33%) and emergency department visits
(-36%) and in the total length of hospital stay
(-34%) were accompanied by an increase in the
mean number of all-cause prescription claims
(?13%) (all P\0.0001) after introduction of
dronedarone (Figs. 1, 2). Cardiovascular- and
AF-related hospitalizations (-35% and -39%),
emergency department visits (-49% and
-53%), and AF-related prescription claims
(?26%), as well as durations of cardiovascular-
and AF-related hospital stay (-36% and -37%)
(all P\0.0001) were affected in a similar
manner (Figs. 1, 2).
Comparison of treatment patterns between
the baseline and follow-up periods revealed
similar levels of coverage with rate-control
therapy (80.3% vs. 77.5%) and anticoagulant
therapy (67.1% vs. 69.1%), but reduced use of
other rhythm-control agents (18.0%) after
introduction of dronedarone. Despite sharp
reductions (C90%) in numbers of claims for
amiodarone and sotalol, the overall mean
number of antiarrhythmic drug claims during
the follow-up period was 55% higher than
during the baseline period, with dronedarone
accounting for most of these (Table 2).
Initiation of dronedarone treatment was also
associated with increases in mean numbers of
prescription claims for anticoagulant drugs
(?22%, P\0.0001), including warfarin (?10%,
P\0.001) and dabigatran (?2,000%,
P\0.0001) (Table 2).
DISCUSSION
The present analysis reinforces the findings of
the ATHENA trial by indicating that the
reductions in cardiovascular hospitalization
obtained with dronedarone in the controlled
clinical trial setting extend to the broader
population of AF/AFL patients—both those
initiating rhythm-control therapy and those
Table 1 continued




Pulmonary disease 765 (13.5) 284 (13.7)
Diabetes 1,285 (22.7) 442 (21.3)
Charlson Comorbidity Index, mean (SD) 1.50 (1.76) 1.51 (1.80)
CHADS2 score, mean (SD) 1.48 (1.14) 1.42 (1.10)
AF atrial ﬁbrillation, AFL atrial ﬂutter, CHADS2 congestive heart failure, history of hypertension, age C75 years, diabetes
mellitus, and past history of stroke or TIA, HMO health maintenance organization, POS point of service plan, PPO
preferred provider organization, SD standard deviation, TIA transient ischemic attack
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switching from other rhythm-control agents—
in real-world practice. These data are of value in
that the ATHENA trial population, which
excluded patients with severe heart failure and
permanent AF, was similar to the current study
population. The cardiovascular outcome benefit
of reduced cardiovascular hospitalizations seen
in the real world helps to validate both the
clinical trial findings from ATHENA and the
recommendations of the American College of
Cardiology Foundation/American Heart
Association/Heart Rhythm Society (ACCF/
AHA/HRS) AF-focused guideline update
regarding dronedarone [21].
The ATHENA trial population comprised
patients with paroxysmal or persistent AF/AFL
who were aged either C75 years (with or
without cardiovascular risk factors) or
\75 years with one or more additional
cardiovascular risk factors. Patients with
recently decompensated heart failure or severe
heart failure [New York Heart Association
(NYHA) class IV] were excluded. Over a mean
follow-up period of 21 months, dronedarone
reduced (inter alia) the risk of first
cardiovascular hospitalization by 26% relative
to placebo [9].
On the basis of the ATHENA trial findings,
dronedarone was initially approved by the US
Food and Drug Administration (FDA) in 2009 to
reduce the risk of cardiovascular hospitalization
in patients with paroxysmal or persistent
AF/AFL, with a recent episode of AF/AFL and
associated cardiovascular risk factors, and in
sinus rhythm or scheduled for cardioversion. A
subsequent FDA review, prompted by the
PALLAS (Permanent Atrial fibriLLation
Outcome Study Using Dronedarone on Top of
Standard Therapy) trial findings [22], led to the
revised recommendation that dronedarone
should be initiated only in patients with non-
permanent AF (but not AFL) who are in sinus
rhythm, and discontinued on progression to
permanent AF [23]. The therapeutic value of
dronedarone, including its risks and benefits,
has been reviewed extensively in several articles
[24–26], with the general consensus that
patients being considered for dronedarone
therapy be carefully selected and monitored to
prevent potential adverse events and drug
interactions. As such, current 2011 American
Fig. 1 Use of inpatient services before and after initiation
of dronedarone treatment. AF atrial ﬁbrillation, CV
cardiovascular, SD standard deviation, SE standard error.
*P\0.0001, intra-group comparison of baseline period vs.
follow-up period
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College of Cardiology/American Heart
Association (ACC/AHA) practice guidelines for
management of AF recommend dronedarone as
a treatment that can be initiated in the
outpatient setting to reduce the need for
cardiovascular hospitalization in patients with
paroxysmal AF or after cardioversion of
persistent AF [21, 27].
The study population, drawn from patients
who initiated dronedarone treatment between
June 2009 and March 2011 following a recent
diagnosis of AF/AFL, is likely to have satisfied
the clinical criteria of the initial (pre-2011)
product label, and appears to have been at
comparable cardiovascular risk to the ATHENA
trial population. By excluding patients with
recent hospitalization for heart failure, it is
likely that any patients with significant heart
failure were removed from the study. Patients
had a high level of baseline cardiovascular/
Fig. 2 Use of outpatient services before and after initiation
of dronedarone treatment. AF atrial ﬁbrillation, CV
cardiovascular, SD standard deviation, SE standard error.
*P\0.0001 for all, intra-group comparison of baseline
period vs. follow-up period
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cardio-metabolic comorbidity, most commonly
hypertension, coronary artery disease, and
diabetes, and were of similar age (mean
68.4 years) to the ATHENA trial population
(mean 71.6 years). Patients were required to
have a minimum of 180 days of continuous use
of dronedarone both to ensure treatment
compliance and to match the treatment
duration of the ATHENA trial. Results from
this real-world population indicated that
initiation of dronedarone treatment resulted
in pronounced reductions in all-cause,
cardiovascular-related, and AF-related hospital
admissions (*40–45%), emergency department
visits (*30–45%), and lengths of hospital stay
(*35–40%), which were offset by modest
increases in office visits (*10–30%) and a
marked increase in AF-related drug
(predominantly dronedarone) prescriptions
(74%) over the following 12 months.
Numerically similar changes in healthcare
resource utilization to those in the full study
population occurred in the Prior Rhythm-
Control cohort over this period; reductions in
all-cause, cardiovascular-related, and AF-related
hospital admissions, emergency department
Fig. 3 Use of AF-related medication before and after
initiation of dronedarone treatment in the full study
population. AF atrial ﬁbrillation, SE standard error. Mean
(SE) number of claims presented per patient/year.
*P\0.0001, intra-group comparison of baseline period
vs. follow-up period
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visits, and lengths of hospital stay were
accompanied by an increase in AF-related
prescriptions.
In clinical practice, AF/AFL patients at high
thromboembolic risk, who represent prime
candidates for dronedarone treatment,
experience high rates of hospitalization, with
approximately 40% requiring readmission
within the first 12 months after their initial
hospitalization for AF/AFL, resulting in a mean
cost per AF hospitalization of US$7,476–8,493
[16, 28]. In keeping with the high volume and
temporal pattern of cardiovascular admissions
displayed by this high-risk patient population,
the study findings suggest that the benefit of
reduced hospital resource utilization associated
with dronedarone is realized promptly, within
12 months of commencing treatment.
With the healthcare costs of AF/AFL
currently estimated at $26 billion annually
[29], and the number of cases of AF/AFL in
the US predicted to rise to more than 8 million
over the next 30–40 years [1], the development
of treatments that can reduce the need for
cardiovascular admission assumes importance
in restraining the growing cost burden of this
condition. The recent ACC and Institute for
Healthcare Improvement-led Hospital to Home
initiative was designed to reduce 30-day
all-cause readmission rates for patients
discharged with heart failure or acute
myocardial infarction by 20% nationwide
[30]. It is feasible that a national quality
initiative of this type might also be applied to
the management of AF/AFL, with the aim of
reducing hospital admissions and improving
the transition of care from the inpatient to
outpatient setting; one element of this would
be improvement of post-discharge medication
management.
Table 2 AF-related prescription drug claims before and after initiation of dronedarone therapy in the full study population
and the prior rhythm-control cohort
Mean (SD) no. prescription claims per PY
Full study population (n5 5,656) Prior rhythm-control cohort (n5 2,080)
Baseline Follow-up Baseline Follow-up
Antiarrhythmic drugs 1.93 (3.11) 7.53 (4.21)*** 4.97 (3.29) 7.69 (4.45)***
Dronedarone 0 7.29 (4.21)*** 0 7.32 (4.43)
Amiodarone 0.79 (1.96) 0.12 (0.54)*** 1.96 (2.77) 0.20 (0.69)***
Sotalol 0.44 (1.68) 0.04 (0.33)*** 1.17 (2.59) 0.06 (0.44)***
Other antiarrhythmic drugs 0.70 (2.16) 0.08 (0.44)*** 1.84 (3.23) 0.10 (0.52)***
Rate-control drugs 5.49 (5.24) 5.66 (6.16)* 5.49 (5.15) 5.65 (6.31)
Calcium channel blockers 1.85 (3.11) 1.90 (3.65) 1.97 (3.21) 1.90 (3.58)
b-blockers 3.07 (3.47) 3.23 (4.05)* 2.89 (3.43) 3.16 (4.18)*
Anticoagulant drugs 2.49 (3.43) 4.11 (4.69)*** 3.27 (3.67) 4.00 (4.51)***
Warfarin 2.47 (3.43) 3.61 (4.58)*** 3.25 (3.67) 3.59 (4.38)**
Dabigatran 0.02 (0.20) 0.50 (1.48)*** 0.02 (0.15) 0.42 (1.31)***
PY patient-year, SD standard deviation
* P\0.01, ** P\0.001, *** P\0.0001, intra-group comparison of baseline vs. follow-up periods
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Limitations of this study include its
retrospective, nonrandomized design, the
absence of a control group, meaning a placebo
effect cannot be eliminated, and reliance on
data from a highly regulated, US-specific,
healthcare system. Use of the MarketScan
databases has the advantage of capturing the
reimbursement policies and practices of
multiple payers; however, the applicability of
the study findings to Medicare patients without
employer-sponsored supplemental insurance
and to the uninsured is uncertain. The
MarketScan databases are also limited to the
diagnostic information that supports claims for
reimbursement, and errors may arise through
coding inaccuracies. Furthermore, there was
little information on the causality and severity
of AF/AFL, and the time interval from disease
diagnosis to initiation of dronedarone therapy
was variable. Given the constraints of the
administrative claims data and the non-
randomized design of the study, it was not
possible to assess the contributions of patient
profile, the AF disease process, and rhythm- or
rate-control therapy to the observed clinical
outcomes. It is unclear whether the patients
switching from Prior Rhythm-Control therapy
were doing so because of treatment failure or on
account of the more favorable tolerability
profile of dronedarone. Although intra-cohort
comparison of baseline versus follow-up
outcomes allowed patients to serve as their
own controls, the absence of a control group
prevented assessment of the potential influence
of disease evolution on the measured outcomes.
In the study, patients were required to have
received dronedarone for at least 180 days.
Thus, the patients receiving a shorter duration
of dronedarone treatment were not evaluated.
Also, the study did not take into consideration
the monitoring requirements for dronedarone
introduced in the post-approval period. The
small increase in office visits observed with
patients receiving dronedarone was not
controlled for, and may have an impact on the
numbers of hospitalizations and emergency
department events. The use of anticoagulation
during the 12-month baseline period appears to
be higher in the Prior Rhythm-Control cohort
than in the full study population (67.1% vs.
56.3% of patients). As a potential hypothesis,
the patients in the Prior Rhythm-Control
cohort may have been considered to have
more severe AF/AFL and/or at a higher risk
of stroke. Similarly, the increase in
anticoagulation use following dronedarone
initiation (coverage rose to *69% of patients
in both groups) may have been a consequence
of the increased number of office visits (i.e.,
improved patient care) and closer adherence to
treatment guidelines. Thus, it cannot be
excluded that some of the benefits associated
with dronedarone may be due to improved
anticoagulation and/or overall patient care.
Finally, patients selected for inclusion in this
study were required to have demonstrated
reasonable persistence (C6 months) with
dronedarone therapy, in keeping with the
ATHENA trial population, whereas in clinical
practice initial rhythm-control therapy is often
associated with high rates of discontinuation
[31].
CONCLUSIONS
This study extends the findings of the ATHENA
trial by indicating that either first- or second-
line treatment with dronedarone substantially
reduces the rate of cardiovascular
hospitalization among AF/AFL patients in real-
world practice. The reduction in number and
duration of hospitalizations that follows
initiation of dronedarone treatment is offset in
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part by a modest increase in office visits and a
more marked increase in AF-related
prescriptions claims (mainly on account of
claims for dronedarone itself).
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